Background
Methods
Subjects
Genotyping
Data analysis
Results
Participants’ features
Characteristics | Cases (n = 592) | Controls (n = 502) | p |
---|---|---|---|
Age (Mean ± SD, years) | 40.53 ± 13.90 | 40.46 ± 18.08 | 0.934a |
Gender (Males/Females) | 326/266 | 275/227 | 0.924b |
WHO grade | |||
I | 43 | ||
II | 335 | ||
III | 149 | ||
IV | 65 | ||
Surgical method | |||
STR | 177 | ||
NTR | 8 | ||
GTR | 407 | ||
Radiotherapy | |||
No | 58 | ||
Conformal radiotherapy | 159 | ||
Gamma knife | 375 | ||
Chemotherapy | |||
No | 349 | ||
Yes | 243 | ||
Survival condition | |||
Survival | 41 | ||
Lost to follow-up | 24 | ||
Death | 527 |
The genotyping results of MIR17HG variants
The correlation between MIR17HG variants and glioma risk
SNP ID | Allele/Genotype | Control | Case | OR (95% CI) | p | FDR-p |
---|---|---|---|---|---|---|
rs17735387 | G | 829 | 964 | 1 | ||
A | 175 | 220 | 1.08 (0.87–1.35) | 0.486 | 0.778 | |
GG | 341 | 395 | 1 | |||
GA | 147 | 174 | 1.02 (0.79–1.33) | 0.871 | 0.909 | |
AA | 14 | 23 | 1.42 (0.72–2.80) | 0.315 | 0.756 | |
GA + AA | 161 | 197 | 1.06 (0.82–1.36) | 0.672 | 0.806 | |
Additive | / | / | 1.08 (0.87–1.34) | 0.488 | 0.732 | |
rs72640334 | C | 916 | 1070 | 1 | ||
A | 86 | 110 | 1.10 (0.81–1.47) | 0.547 | 0.772 | |
CC | 418 | 487 | 1 | |||
CA | 80 | 96 | 1.03 (0.74–1.43) | 0.860 | 0.938 | |
AA | 3 | 7 | 2.01 (0.51–7.83) | 0.316 | 0.689 | |
CA + AA | 83 | 103 | 1.07 (0.78–1.46) | 0.696 | 0.795 | |
Additive | / | / | 1.09 (0.82–1.47) | 0.550 | 0.733 | |
rs7318578 | A | 714 | 768 | 1 | ||
C | 290 | 412 | 1.32 (1.10–1.58) | 2.63 × 10−3 | 0.032 | |
AA | 257 | 294 | 1 | |||
AC | 200 | 180 | 0.79 (0.61–1.02) | 0.073 | 0.438 | |
CC | 45 | 116 | 2.25 (1.54–3.31) | 3.18 × 10–5* | 0.001 | |
AC + CC | 245 | 296 | 1.06 (0.83–1.34) | 0.654 | 0.826 | |
Additive | / | / | 1.26 (1.07–1.49) | 6.23 × 10−3 | 0.050 | |
rs7336610 | T | 527 | 602 | 1 | ||
C | 475 | 580 | 1.07 (0.90–1.27) | 0.438 | 0.809 | |
TT | 141 | 144 | 1 | |||
TC | 245 | 314 | 1.26 (0.94–1.67) | 0.119 | 0.476 | |
CC | 115 | 133 | 1.13 (0.80–1.59) | 0.477 | 0.818 | |
TC + CC | 360 | 447 | 1.22 (0.93–1.59) | 0.157 | 0.419 | |
Additive | / | / | 1.07 (0.90–1.27) | 0.433 | 0.866 | |
rs75267932 | A | 879 | 1061 | 1 | ||
G | 125 | 123 | 0.82 (0.63–1.06) | 0.130 | 0.446 | |
AA | 385 | 479 | 1 | |||
AG | 109 | 103 | 0.76 (0.56–1.03) | 0.073 | 0.438 | |
GG | 8 | 10 | 1.01 (0.39–2.58) | 0.988 | 0.988 | |
AG + GG | 117 | 113 | 0.78 (0.58–1.04) | 0.089 | 0.427 | |
Additive | / | / | 0.82 (0.63–1.07) | 0.138 | 0.414 |
SNP ID | Allele/Genotype | OR (95% CI) | p | FDR-p | OR (95% CI) | p | FDR-p |
---|---|---|---|---|---|---|---|
Age (year) | ≥ 40 | < 40 | |||||
rs17735387 | G | 1 | 1 | ||||
A | 0.79 (0.59–1.07) | 0.128 | 0.400 | 1.53 (1.11–2.11) | 9.05 × 10− 3 | 0.109 | |
GG | 1 | 1 | |||||
GA | 0.73 (0.51–1.05) | 0.093 | 0.465 | 1.45 (0.98–2.16) | 0.065 | 0.142 | |
AA | 0.87 (0.35–2.16) | 0.765 | 0.911 | 3.27 (1.09–9.80) | 0.034 | ||
GA + AA | 0.74 (0.52–1.06) | 0.101 | 0.421 | 1.57 (1.07–2.30) | 0.021 | 0.101 | |
Additive | 0.80 (0.59–1.08) | 0.152 | 0.380 | 1.56 (1.12–2.18) | 8.55 × 10−3 | 0.205 | |
rs7318578 | A | 1 | 1 | ||||
C | 1.27 (0.99–1.62) | 0.063 | 0.525 | 1.37 (1.05–1.79) | 0.020 | 0.120 | |
AA | 1 | 1 | |||||
AC | 0.64 (0.44–1.02) | 0.051 | 0.188 | 0.94 (0.63–1.40) | 0.754 | 0.952 | |
CC | 2.46 (1.42–4.28) | 1.41 × 10–3* | 0.035 | 1.88 (1.08–3.28) | 0.026 | 0.089 | |
AC + CC | 0.92 (0.66–1.28) | 0.606 | 0.947 | 1.15 (0.80–1.64) | 0.459 | 0.648 | |
Additive | 1.22 (0.97–1.54) | 0.087 | 0.544 | 1.24 (0.97–1.60) | 0.092 | 0.170 | |
rs7336610 | T | 1 | 1 | ||||
C | 1.17 (0.93–1.48) | 0.184 | 0.418 | 1.35 (1.06–1.73) | 0.016 | 0.128 | |
TT | 1 | 1 | |||||
TC | 1.35 (0.90–2.03) | 0.144 | 0.400 | 1.56 (1.02–2.39) | 0.041 | 0.109 | |
CC | 1.35 (0.84–2.16) | 0.210 | 0.438 | 1.72 (1.02–2.92) | 0.044 | 0.106 | |
TC + CC | 1.35 (0.92–1.98) | 0.123 | 0.439 | 1.61 (1.07–2.41) | 0.022 | 0.088 | |
Additive | 1.16 (0.92–1.47) | 0.213 | 0.410 | 1.33 (1.02–1.73) | 0.034 | 0.102 | |
Gender | Male | Female | |||||
rs7318578 | A | 1 | 1 | ||||
C | 1.18 (0.93–1.50) | 0.183 | 0.488 | 1.53 (1.16–2.01) | 2.49 × 10–3* | 0.029 | |
AA | 1 | 1 | |||||
AC | 0.70 (0.49–1.05) | 0.054 | 0.588 | 0.90 (0.61–1.33) | 0.606 | 0.007 | |
CC | 1.80 (1.10–2.95) | 0.020 | 0.480 | 3.08 (1.67–5.67) | 3.19 × 10–4* | 0.871 | |
AC + CC | 0.93 (0.67–1.28) | 0.635 | 0.802 | 1.24 (0.87–1.77) | 0.234 | 0.769 | |
Additive | 1.15 (0.92–1.43) | 0.226 | 0.493 | 1.43 (1.11–1.84) | 5.96 × 10−3 | 0.046 |
SNP ID | Allele/Genotype | I-II | III-IV | OR (95% CI) | p | FDR-p |
---|---|---|---|---|---|---|
rs7336610 | T | 400 | 202 | 1 | ||
C | 354 | 226 | 1.26 (1.00–1.60) | 0.053 | 0.221 | |
TT | 103 | 41 | 1 | |||
TC | 194 | 120 | 1.58 (1.02–2.43) | 0.039 | 0.244 | |
CC | 80 | 53 | 1.72 (1.04–2.86) | 0.036 | 0.300 | |
TC + CC | 274 | 173 | 1.62 (1.07–2.45) | 0.022 | 0.550 | |
Additive | / | / | 1.31 (1.02–1.68) | 0.035 | 0.438 |
The correlation between MIR17HG variants and glioma prognosis
SNP ID | Genotype | OS | PFS | ||||||
---|---|---|---|---|---|---|---|---|---|
Event/ Total | SR (1−/3-year) | MST (month) | Log-rank p | Event/ Total | SR (1−/3-year) | MST (month) | Log-rank p | ||
Overall | |||||||||
rs17735387 | GG | 356/395 | 0.299/0.082 | 11.0 | 0.070 | 355/394 | 0.157/0.088 | 8.0 | 0.026 |
GA | 153/174 | 0.360/0.101 | 12.0 | 150/170 | 0.216/0.094 | 8.0 | |||
AA | 18/23 | 0.435/− | 12.0 | 18/23 | 0.304/− | 9.0 | |||
rs72640334 | CC | 433/487 | 0.319/0.092 | 11.0 | 0.365 | 430/483 | 0.179/0.092 | 8.0 | 0.470 |
CA | 86/96 | 0.333/0.082 | 10.0 | 85/95 | 0.179/0.093 | 8.0 | |||
AA | 7/7 | 0.143/− | 10.0 | 7/7 | 0.286/− | 8.0 | |||
rs7318578 | AA | 263/294 | 0.335/0.085 | 12.0 | 0.755 | 262/293 | 0.192/0.083 | 8.0 | 0.527 |
AC | 160/180 | 0.306/0.093 | 11.0 | 159/178 | 0.163/0.097 | 8.0 | |||
CC | 102/116 | 0.319/0.111 | 11.0 | 101/115 | 0.176/− | 8.0 | |||
rs7336610 | TT | 129/144 | 0.326/0.095 | 11.0 | 0.740 | 129/144 | 0.174/0.096 | 8.0 | 0.516 |
TC | 281/314 | 0.296/0.085 | 11.0 | 279/312 | 0.167/0.089 | 8.0 | |||
CC | 116/133 | 0.381/0.095 | 12.0 | 114/130 | 0.221/0.098 | 8.0 | |||
rs75267932 | AA | 425/479 | 0.323/0.091 | 11.0 | 0.766 | 422/475 | 0.185/0.092 | 8.0 | 0.634 |
AG | 92/103 | 0.311/0.095 | 10.0 | 91/102 | 0.176/0.097 | 8.0 | |||
GG | 10/10 | 0.400/− | 12.0 | 10/10 | 0.100/− | 8.0 | |||
Low-grade glioma (I-II) | |||||||||
rs17735387 | GG | 232/260 | 0.292/0.090 | 11.0 | 0.032 | 232/260 | 0.158/0.093 | 8.0 | 0.013 |
GA | 86/102 | 0.398/0.149 | 12.0 | 84/100 | 0.255/0.135 | 9.0 | |||
AA | 12/16 | 0.500/− | 12.0 | 12/16 | 0.375/− | 9.0 | |||
Females | |||||||||
rs72640334 | CC | 196/221 | 0.335/0.100 | 12.0 | 0.035 | 195/219 | 0.168/0.094 | 8.0 | 0.049 |
CA | 36/39 | 0.205/− | 9.0 | 35/38 | 0.105/− | 6.0 | |||
AA | 6/6 | 0.167/− | 10.0 | 6/6 | −/− | 8.0 | |||
Age ≥ 40 years | |||||||||
rs17735387 | GG | 217/232 | 0.246/0.051 | 10.0 | 0.002 | 216/231 | 0.134/0.059 | 8.0 | 0.002 |
GA | 78/86 | 0.360/0.081 | 12.0 | 78/86 | 0.178/0.080 | 8.0 | |||
AA | 7/11 | 0.303/− | 16.0 | 7/11 | 0.545 | 13.0 |
SNP ID | Genotype | Univariate | Multivariate a | ||||||
---|---|---|---|---|---|---|---|---|---|
OS | PFS | OS | PFS | ||||||
HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | ||
Overall | |||||||||
rs17735387 | GG | 1 | 1 | 1 | 1 | ||||
GA | 0.85 (0.70–1.03) | 0.097 | 0.83 (0.69–1.01) | 0.059 | 0.84 (0.69–1.01) | 0.067 | 0.82 (0.68–0.99) | 0.042 | |
AA | 0.70 (0.43–1.12) | 0.136 | 0.66 (0.41–1.07) | 0.089 | 0.84 (0.46–1.19) | 0.211 | 0.71 (0.44–1.14) | 0.158 | |
rs72640334 | CC | 1 | 1 | 1 | 1 | ||||
CA | 1.08 (0.86–1.36) | 0.508 | 1.07 (0.85–1.35) | 0.560 | 1.08 (0.85–1.37) | 0.520 | 1.09 (0.86–1.38) | 0.467 | |
AA | 1.56 (0.74–3.29) | 0.247 | 1.44 (0.68–3.05) | 0.335 | 1.25 (0.58–2.66) | 0.569 | 1.20 (0.56–2.56) | 0.633 | |
rs7318578 | AA | 1 | 1 | 1 | 1 | ||||
AC | 1.07 (0.88–1.30) | 0.493 | 1.11 (0.91–1.35) | 0.310 | 1.07 (0.88–1.30) | 0.516 | 1.10 (0.90–1.34) | 0.353 | |
CC | 1.03 (0.82–1.30) | 0.776 | 1.04 (0.82–1.30) | 0.762 | 1.05 (0.83–1.32) | 0.701 | 1.04 (0.83–1.31) | 0.725 | |
rs7336610 | TT | 1 | 1 | 1 | 1 | ||||
TC | 1.00 (0.81–0.23) | 0.98 | 0.99 (0.81–1.23) | 0.957 | 0.96 (0.78–1.18) | 0.703 | 0.96 (0.78–1.18) | 0.698 | |
CC | 0.93 (0.72–1.19) | 0.549 | 0.89 (0.69–1.15) | 0.381 | 0.91 (0.71–1.17) | 0.480 | 0.89 (0.69–1.15) | 0.375 | |
rs75267932 | AA | 1 | 1 | 1 | 1 | ||||
AG | 1.07 (0.85–1.33) | 0.585 | 1.07 (0.85–1.34) | 0.568 | 1.04 (0.83–1.31) | 0.727 | 1.05 (0.84–1.32) | 0.671 | |
GG | 1.14 (0.61–2.14) | 0.675 | 1.24 (0.66–2.32) | 0.502 | 1.17 (0.62–2.20) | 0.633 | 1.24 (0.66–2.34) | 0.502 | |
Low-grade glioma (I-II) | |||||||||
rs17735387 | GG | 1 | 1 | 1 | 1 | ||||
GA | 0.77 (0.60–0.99) | 0.042 | 0.75 (0.58–0.97) | 0.024 | 0.75 (0.58–0.96) | 0.024 | 0.73 (0.57–0.94) | 0.016 | |
AA | 0.64 (0.36–1.15) | 0.138 | 0.62 (0.35–1.11) | 0.110 | 0.68 (0.38–1.22) | 0.195 | 0.70 (0.39–1.26) | 0.233 | |
Females | |||||||||
rs72640334 | CC | 1 | 1 | 1 | |||||
CA | 1.49 (1.05–2.14) | 0.027 | 1.48 (1.03–2.12) | 0.034 | 0.89 (0.65–1.21) | 0.454 | 0.88 (0.65–1.20) | 0.427 | |
AA | 1.50 (0.66–3.38) | 0.332 | 1.35 (0.60–3.05) | 0.470 | 2.05 (0.28–4.87) | 0.477 | 2.62 (0.36–8.99) | 0.342 | |
Age ≥ 40 years | |||||||||
rs17735387 | GG | 1 | 1 | 1 | 1 | ||||
GA | 1.30 (1.00–1.68) | 0.500 | 0.80 (0.62–1.04) | 0.098 | 0.77 (0.59–1.00) | 0.047 | 0.79 (0.61–1.03) | 0.084 | |
AA | 1.00 (0.74–1.35) | 0.993 | 0.36 (0.17–0.76) | 0.007 | 0.46 (0.22–1.00) | 0.049 | 0.45 (0.21–0.97) | 0.042 |